John A. Herrmann III - May 28, 2021 Form 4 Insider Report for NOVAVAX INC (NVAX)

Signature
/s/ John A. Herrmann III
Stock symbol
NVAX
Transactions as of
May 28, 2021
Transactions value $
-$388,815
Form type
4
Date filed
6/2/2021, 04:59 PM
Next filing
Jun 29, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise $11.5K +416 +151.27% $27.60 691 May 28, 2021 Direct F1
transaction NVAX Common Stock Options Exercise $19.2K +417 +60.35% $46.00* 1.11K May 28, 2021 Direct F1
transaction NVAX Common Stock Options Exercise $12.3K +2.06K +186.1% $5.95 3.17K May 28, 2021 Direct F1
transaction NVAX Common Stock Sale -$128K -864 -27.26% $147.85* 2.31K May 28, 2021 Direct F1, F2
transaction NVAX Common Stock Sale -$165K -1.11K -48.09% $148.88* 1.2K May 28, 2021 Direct F1, F3
transaction NVAX Common Stock Sale -$77.5K -517 -43.19% $149.81* 680 May 28, 2021 Direct F1, F4
transaction NVAX Common Stock Sale -$36.3K -240 -35.29% $151.08* 440 May 28, 2021 Direct F1, F5
transaction NVAX Common Stock Sale -$14.5K -95 -21.59% $152.11* 345 May 28, 2021 Direct F1, F6
transaction NVAX Common Stock Sale -$10.7K -70 -20.29% $153.49* 275 May 28, 2021 Direct F1, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Stock Option (Right to Buy) Options Exercise $0 +416 +16.56% $0.00 2.93K May 28, 2021 Common Stock 416 $27.60 Direct F1, F8
transaction NVAX Stock Option (Right to Buy) Options Exercise $0 +417 +5.55% $0.00 7.93K May 28, 2021 Common Stock 417 $46.00 Direct F1, F9
transaction NVAX Stock Option (Right to Buy) Options Exercise $0 +2.06K +3.7% $0.00 57.8K May 28, 2021 Common Stock 2.06K $5.95 Direct F1, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.42 to $148.40, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F3 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.45 to $149.41, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F4 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.47 to $150.40, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F5 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.68 to $151.67, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F6 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.78 to $152.56, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F7 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.43 to $153.82, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F8 Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
F9 Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
F10 Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.